

Endo Pharma to pay US\$ 23 mn to LecTec to settle patent litigation

Saturday, November 14, 2009 14:00 IST

Chadds Ford, Pennsylvania

Endo Pharmaceuticals has reached a settlement with LecTec Corporation on outstanding patent litigation related to LecTec's US Patent Nos. 5,536,263 and 5,741,510.

Endo Pharmaceuticals has agreed to make a one-time, US\$ 23 million payment for the exclusive license to these two patents for use in the field of prescription pain medicines and treatment. "We are pleased to add these patents to our IP inventory especially as they relate to Lidoderm," said Caroline Manogue, executive vice president and chief legal officer of Endo Pharmaceuticals.

Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain, prostate cancer and the early onset of puberty in children, or central precocious puberty (CPP).